Skip to main content

Advertisement

Single-nucleotide polymorphisms in the folate pathway are associated with response to methotrexate treatment in juvenile idiopathic arthritis

Article metrics

  • 1323 Accesses

Background

Insight into factors associated with outcomes of methotrexate (MTX) treatment may contribute to more individualized treatment of juvenile idiopathic arthritis (JIA). In this study, associations of SNPs in genes encoding folate pathway enzymes with MTX efficacy and adverse effects in JIA patients were evaluated.

Methods

Genotypes were determined in an observational cohort of 183 JIA patients that had been systematically followed at 3 months intervals. The following SNPs were determined: methylenetetrahydrofolate reductase (MTHFR) 677C>T and 1298A>C, methionine synthase reductase (MTRR) 66A>G, thymidylate synthase (TS) 2R/3R and Reduced Folate Carrier (RFC) 80G>A. MTX efficacy and adverse effects were compared among genotypes during the first year of treatment and at long-term follow up.

Results

The MTHFR 1298CC variant was associated with MTX efficacy (OR 3.3, 95%-CI 1.0–10.2) after 3 months, while MTHFR 677T-allele carriers had a lower chance of early good clinical response (OR 0.4, 95%-CI 0.2–0.9). The MTHFR 1298C-allele was also associated with MTX efficacy after long-term follow-up (OR 1.8, 95%-CI 1.0–3.4).

Regarding adverse effects, MTHFR 677TT was associated with liver toxicity in the first year of MTX use (OR 10.4, 95%-CI 2.2–48.6). MTRR 66G-allele carriers were more likely to have gastrointestinal intolerance during the first 3 months of treatment (OR 9.9, 95%-CI 1.3–76.9).

Conclusion

Polymorphisms in the MTHFR and MTRR genes are associated with methotrexate efficacy and adverse effects. Genotyping may add in predicting response to MTX treatment in JIA patients.

Author information

Correspondence to MW Heijstek.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Heijstek, M., Wulffraat, N., Eken, Y. et al. Single-nucleotide polymorphisms in the folate pathway are associated with response to methotrexate treatment in juvenile idiopathic arthritis. Pediatr Rheumatol 6, P15 (2008) doi:10.1186/1546-0096-6-S1-P15

Download citation

Keywords

  • Juvenile Idiopathic Arthritis
  • Juvenile Idiopathic Arthritis Patient
  • Methylenetetrahydrofolate Reductase
  • Good Clinical Response
  • Reduce Folate Carrier